Supernus Pharmaceuticals Inc (Supernus Pharmaceuticals) develops and commercializes products for the treatment of central nervous system diseases. It operates through one reportable segment. The company's marketed products include Oxtellar XR, Apokyn, Xadago, Myobloc and Trokendi XR. Trokendi XR is an oral extended-release topiramate formulation, administered once-daily. The product is approved in the US as initial monotherapy for the treatment of partial onset or primary generalized tonic-clonic seizures in patients aged six years and above, and as adjunctive therapy for similar seizures or with seizures associated with Lennox-Gastaut syndrome in patients aged six years and above.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company's R&D efforts focus on the development of product candidates for the treatment of central nervous system diseases including attention deficit hyperactivity disorder (ADHD); severe pediatric epilepsy disorders; and depression. Major pipeline products include SPN-830, SPN-817 and SPN-820. Major technology platforms include Microtrol, Solutrol, and EnSoTrol (osmotic delivery system). In FY2022, the company spent US$74.6 million on its R&D, which as a percentage of revenue, stood at 11.2%. Consists of ten US patents and one issued patent each in China, Canada related to Trokendi XR. Oxtellar XR obtained twelve US patents, two issued patents in both Europe and one patent each in China and Canada, XADAGO obtained three US patents. The company also has several patent applications associated with its other pipeline products. Its SPN-817 has two US patents and filed patent applications in the US, and China.